Evotec SE (EVO) announced progress within the strategic partnership with Bristol Myers Squibb. Evotec received a $25 million payment to progress further research. A first programme, EVT8683, was in-licensed by Bristol Myers Squibb in September 2021 as BMS-986419. A Phase II study for BMS-986419 is scheduled to commence in 2024.
The companies entered their strategic neuroscience collaboration in December 2016. In March 2023, the companies extended and expanded the partnership for an additional 8 years.
Cord Dohrmann, Chief Scientific Officer of Evotec, said: "As the first asset from our neuroscience partnership with Bristol Myers Squibb is moving towards a Phase II study, our partnership is still growing in the drug discovery phase as well."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.